logo
  

U.S. Government To Acquire 10 Mln Treatment Courses Of COVID-19 Antiviral Candidate From Pfizer

Pfizer Inc. (PFE) has agreed to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID, to the U.S. government. The agreement is subject to regulatory authorization from the FDA. Currently, the company is seeking Emergency Use Authorization of PAXLOVID with the FDA.

The U.S. government will acquire 10 million treatment courses beginning later in the year and concluding in 2022. Pfizer will receive $5.29 billion from the government, pending and contingent upon regulatory authorization.

"We were thrilled with the recent results of our phase 2/3 interim analysis, which showed overwhelming efficacy of PAXLOVID in reducing the risk of hospitalization among high-risk patients treated within three days of symptom onset by almost 90% and with no deaths," said Albert Bourla, CEO, Pfizer.

Pfizer noted that it has also entered into advance purchase agreements with several other countries and has started bilateral outreach to approximately 100 countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Deutsche Telekom AG on Friday raised its fiscal 2022 adjusted earnings forecast after reporting significantly higher net profit in its first quarter. Shares of the German telecom major were gaining around 1 percent in the morning trading in Germany. For fiscal 2022, the company now expects to post adjusted EBITDA AL of more than 36.6 billion euros. Yamaha Motor Corp. USA, affiliated to Japanese automaker Yamaha Motor Co. Ltd., is recalling about 4,130 units of Wolverine RMAX Off-Road Side-By-Side vehicles citing fire and explosion hazards, the U.S. Consumer Product Safety Commission said. Van Leeuwen Ice Cream recalled 2,185 frozen 14 oz pints of its non-dairy frozen dessert product "Oat Milk Brown Sugar Chunk" for potentially containing undeclared specific trace of allergens such as tree nuts, cashews and pistachios, the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT